DryVax is a technology that allows the manufacture of vaccines that have aluminum-containing adjuvants into a dosage form that is not sensitive to freezing, intentionally or unintentionally. This technology can have a profound impact on the existing vaccine supply-chain because cold-chain storage accounts for up to 80% of the financial cost of vaccination, and an estimated 75-100% of the vaccine shipments are exposed to freezing temperatures resulting in costly waste and the loss of nearly half of all global vaccine supplies. This technology will also open markets that lack cold-chain storage and as a result were unreachable for broad vaccine distribution.
How TVL Helped: TVL researched potential drugs that would be a good fit for DryVax technology. Additionally work focused on determining countries that are optimal for the final product.